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Abstract
To investigate how cholinergic systems regulate aspects of the sleep disorder narcolepsy, we video-monitored mice lacking
both orexin (hypocretin) receptors (double knockout; DKO mice) while pharmacologically altering cholinergic transmission.
Spontaneous behavioral arrests in DKO mice were highly similar to those reported in orexin-deficient mice and were never
observed in wild-type (WT) mice. A survival analysis revealed that arrest lifetimes were exponentially distributed indicating
that random, Markovian processes determine arrest lifetime. Low doses (0.01, 0.03 mg/kg, IP), but not a high dose (0.08 mg/
kg, IP) of the cholinesterase inhibitor physostigmine increased the number of arrests but did not alter arrest lifetimes. The
muscarinic antagonist atropine (0.5 mg/kg, IP) decreased the number of arrests, also without altering arrest lifetimes. To
determine if muscarinic transmission in pontine areas linked to REM sleep control also influences behavioral arrests, we
microinjected neostigmine (50 nl, 62.5 mM) or neostigmine + atropine (62.5 mM and 111 mM respectively) into the nucleus
pontis oralis and caudalis. Neostigmine increased the number of arrests in DKO mice without altering arrest lifetimes but did
not provoke arrests in WT mice. Co-injection of atropine abolished this effect. Collectively, our findings establish that
behavioral arrests in DKO mice are similar to those in orexin deficient mice and that arrests have exponentially distributed
lifetimes. We also show, for the first time in a rodent narcolepsy model, that cholinergic systems can regulate arrest
dynamics. Since perturbations of muscarinic transmission altered arrest frequency but not lifetime, our findings suggest
cholinergic systems influence arrest initiation without influencing circuits that determine arrest duration.
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Introduction
Narcolepsy is a human sleep disorder characterized by excessive
daytime sleepiness, sleep paralysis, hypnagogic hallucinations and
cataplexy – epochs of muscle atonia triggered by strong emotions
[1]. Evidence indicates that the disease results from a deficiency in
orexin neuropeptides [2,3]. These neuropeptides (also called the
hypocretins) are synthesized by lateral hypothalamic neurons [4,5]
having extensive central projections [6]. Two G-protein coupled
orexin receptors (OX1R; OX2R) have been identified [5] and are
expressed throughout the brain in a partly overlapping pattern
[7,8]. Studies linking orexin deficiency to human narcolepsy
quickly followed upon the discoveries that prepro-peptide null
mice have a narcolepsy phenotype [9] and canines, with heritable
narcolepsy, have a null mutation in the OX2R [10]. Interestingly,
OX2R null mice are less severely affected [11], presumably due to
residual OX1R signaling. Preliminary reports indicate that OX1R
null mice lack narcolepsy symptoms and do not have cataplexy
[12,13] while double orexin receptor knockout (DKO) mice
exhibit narcolepsy with cataplexy [13,14].
Despite these clues, it remains unclear how the loss of orexin
signaling produces narcolepsy. Orexin synaptic targets at the
pontomesencephalic junction, including noradrenergic neurons of
the locus coeruleus, the serotonergic neurons of the raphe system and
the cholinergic neurons of the laterodorsal tegmental (LDT) and
pedunculopontine (PPT) nuclei, are candidates for mediating arousal-
related functions of orexin [15]. Moreover, these structures have long
been thought to function in generating EEG andmuscle tone changes
associated with REM sleep. Several lines of evidence support a model
in which reciprocal synaptic interactions between REM-on cholin-
ergic and REM-off monaminergic neurons form a switching
mechanism that determines the onset and duration of REM sleep
and its associated signs such as muscle atonia (for review see [16]).
Indeed, results from studies in narcoleptic canines indicate an
imbalance in brainstem cholinergic and monoaminergic transmission
contributes to the expression of cataplexy, as might be expected from
this model (for review see [17]). Nevertheless, accumulating evidence
from rodent studies [18,19,20] has challenged the importance of
cholinergic and monoaminergic interactions in the generation of
REM-sleep. This work has led to models in which interconnected
REM-off and REM-on GABAergic neurons form the core elements
of a REM sleep switch. In these models, cholinergic and mono-
aminergic neurons function outside the switching mechanism,
although their roles have not yet been defined (for review see [21,22]).
In contrast to canine narcolepsy, little is known about the
pharmacology of rodent narcolepsy/cataplexy. We therefore
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characterized for the first time the dynamics of narcoleptic attacks
in DKO mice and determined whether altered cholinergic
transmission, produced by cholinesterase inhibitors and atropine,
affect these dynamics. We found that narcoleptic arrests of DKO
mice appear to be a phenocopy of those in orexin deficient mice
and that arrest lifetimes follow an exponential distribution. We
also found that enhanced cholinergic transmission increased the
number but not the lifetime of narcoleptic arrests in DKO mice,
but did not produce arrests in wild-type mice. These findings
imply that cholinergic outflow in orexin-signaling deficient mice
can regulate transitions into, but not out of, the arrest state. This is
consistent with cholinergic systems influencing arrest initiation
circuitry without being part of the circuits determining arrest
duration.
Methods
Ethics Statement
All protocols used in this study were reviewed and approved by
the Institutional Animal Care and Use Committee of New York
Medical College and were compliant with NIH guidelines for
ethical treatment of animals.
Mice
DKO breeder mice from the Yanagisawa laboratory were re-
derived by embryo transfer at New York Medical College and the
offspring from these re-derived mice were used for this study.
DKO mice were originally created by cross breeding heterozygous
progeny of homozygous single receptor knockouts (OX1R-
KO6OX2RKO). The making of OX2RKO mice have been
described in detail [11] and the making of OX1RKO mice has
been described in a preliminary report [12] and will be described
completely in a future publication that will also include
polysomnography data from both DKO and OX1RKO mice.
Background control WT mice were derived from the WT
littermates resulting from heterozygous OX2RKO crosses. Hence
both strains of mice used in these experiments had the same mixed
C57Bl66129/SvEv genetic background.
Genotyped male DKO and WT mice aged 12–20 weeks old (28–
32 g) were housed individually in rat cages (10.250W618.750D680H)
equipped with a running wheel with unlimited access to water and
standard lab chow. The mice were maintained on a 12:12 light-dark
cycle, with 7:00 AM as the beginning of the light phase. Mice were
acclimated to these new home cages for five days before recording
began. Cage bedding was replaced once every week after a video
recording session. All video recording sessions lasted for three hours
and began a half hour prior to lights out, a period when the most
number of cataplexy-like attacks were expected [9].
Video recording and behavioral analysis
Infrared sensitive video cameras (MCM electronics) were
mounted onto the top of home cages and video streams from
these cameras were digitized simultaneously at 3206240 pixels/
frame at 15 frames per second by an Axis 241Q video server (Axis
Communication, Lund Sweden) and recorded to a MacBook Pro.
SecuritySpy software (Bensoftware) running on the Mac was used
to configure the server and to capture, compress (MPEG-4) and
time-stamp the video. Behavioral scoring was performed using
Annotation (Saysosoft) software. Mice were randomly assigned to
one of two observers for scoring. To achieve congruent scoring
criteria, a separate cohort of mice were scored by both observers
until they were consistent in their criteria prior to working with the
mice used for these experiments. Any behavior deemed ambiguous
by one observer in the experimental mice was reviewed by both
observers to assign a score. Onset and duration data for behavioral
events were then imported into custom analysis procedures
developed in Igor Pro (Wavemetrics, Lake Oswego, OR, USA)
which allowed us to summarize and compare behavioral events
between individual mice and across genotypes. Computation of
cumulative distributions or event duration and survival curves was
done using custom procedures in Igor Pro. Curve fitting was
accomplished by fitting survival distributions to built-in Igor Pro
functions for a shifted exponential (y(x) = y0+Aexp(2(x-x0)/tau))
and a power function (y(x) = y0+Ax2alpha) with x0 set to 5 s, and y0
constrained to be 0, using their built-in implementation of the
Levenberg-Marquardt algorithm. Additional tabulation was done
using Excel (Microsoft).
Systemic injections
To investigate the influence of cholinergic signaling on
behavioral arrests, 20 mice (n = 10 DKO; n= 10 WT) received
IP injections of either physiological saline (0.9% NaCl) or
physostigmine dissolved in saline (0.01, 0.03, and 0.08 mg/kg
body weight; Fisher Scientific cat# 50809809) a half hour prior to
video recording. Each mouse received a single injection once every
5 days for a total of 4 injections in random order. In a separate
series of measurements, seventeen mice (DKO, n=10, WT, n= 7)
received atropine (0.5 mg/kg body weight; Fisher Scientific cat #
ICN10081301) or saline injections in random order a half hour
prior to recording (one hour before the start of the dark cycle).
Pontine Microinjections
Twenty mice (DKO, n=11; WT, n=9) were each surgically
implanted with a guide cannula (PlasticsOne, Roanoke, VA)
following a modified protocol previously published [23]. Mice were
anesthetized with ketamine (100 mg/kg)/xylazine (3.5 mg/kg) ip
and placed in a Kopf (Tujunga, CA, USA) model 962 stereotaxic
frame with non-rupture, cup-type ear bars. The skull was exposed
and a 26 gauge stainless steel guide cannula (PlasticsOne) was
stereotaxically implanted at a depth 2 mm above the pontine
reticular nuclei (24.7 mm posterior and 20.7 mm lateral from
bregma). A dummy cannula of the same length was placed into the
guide cannula and Cerebond (PlasticsOne) was used to adhere the
assembly to the skull. Following a 1 week recovery period, each
mouse received an injection once every 4 or 5 days a half hour prior
to recording. Recordings began 30 minutes before lights-off and
continued for a total of three hours. On the day of injection, the
dummy cannula was replaced with a 32 gauge injection cannula.
The injection cannula extended 2 mm past the guide cannula to
reach the nucleus pontis oralis (PnO) or caudalis (PnC). A total of
50 nl was delivered over a 6 minute period via a microinjector (IM-
1, Narashige, Japan) and a 1 ml syringe (series 7000, Hamilton,
Reno NV). The internal cannula was kept in place for 1 minute
post-injection to allow additional time for diffusion from the
injection site. Injections consisted of either ACSF (artificial cerebral
spinal fluid; NaCl (124 mM), KCl (5 mM), NaH2PO4 (1.2 mM),
CaCl2 (2.7 mM), MgSO4 (1.2 mM), NaHCO3 (26 mM) and D-
Glucose (10 mM)), neostigmine dissolved in ACSF (Fisher Scientific
cat # 338440050, 62.5 mM, 0.95 ng) or neostigmine and atropine
dissolved in ACSF (62.5 mM, 0.95 ng neostigmine; and 111 mM,
3.8 ng atropine) were given in a random order a half hour prior to
the recording session. Neostigmine, like physostigmine, is a
cholinesterase inhibitor, but does not cross the blood brain barrier.
Coleman et. al. found that a 50 nl microinjection of 0.88 mM
neostigmine into the PnO induced REM-like state and decreased
REM sleep latency in C57Bl6 mice [23]. In preliminary studies, we
found that such high concentrations of neostigmine greatly
increased the amount of time the mice spent in the inactive state.
Narcolepsy in Orexin Receptor Null Mice
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We therefore reduced the concentration to levels that did not
produce obvious effects on general behavior.
Histology
A day after the last injection, the mice were perfused through
the heart with saline (40 mls) followed by 4% paraformaldehyde
(PFA; 1000 mls). The brains were then removed and submerged in
4% PFA overnight followed by 30% sucrose. Brains were
sectioned on a cryostat at 50 mm, were processed with cresyl
violet staining and examined by brightfield microscopy (Olympus
BX60) to verify cannula placements. Location of the injections
sites were then plotted onto standard drawings from an atlas [24].
Statistical Analyses
All data is shown as mean 6 standard error of the mean.
Differences between means were determined by two-way ANO-
VAs with mouse and treatment as factors using DataDesk 6.2
software (Data Description, Ithaca, New York) and protected
Fischer’s Least Square Difference post-hoc testing where signifi-
cance was taken as p,0.05 when multiple means were compared.
Additional non-parametric Kruskal-Wallis post-hoc testing was
performed using NCSS software (NCSS, Kaysville, Utah) which
confirmed the results from the parametric post-hoc tests. Bout
duration distributions were compared using the Kolmogorov-
Smirnov (K-S) test implemented in Igor Pro software with
significance set at p,0.05.
Results
In order to gauge the overall level of mouse activity during the
recording period we used two measures. The first was the amount
of time the mice spent interacting with the running wheel. As
expected, both WT and DKO mice exhibited an increased wheel
activity in the dark period (Fig. 1A). We found that there was no
significant difference between genotypes in the average time mice
spent interacting with the wheel over the three hour recording
time (WT: 3151.06382.8 s; DKO: 2539.76320.3 s; p.0.05;
Fig. 1B). In addition, we found no difference between genotypes in
the distribution of wheel running bout durations or the mean bout
duration (mean bout duration WT: 90.9614.4 s vs. DKO:
84.3610.6 s; p.0.05). Of course, there may have been differences
in speed and distance covered, as reported for the orexin ligand
knockout [25] but we only measured the time interacting with the
wheel. It therefore seemed that the DKO mice were as interested
by the wheel as were the WT mice.
As a second indicator of activity, we measured the time spent in
behaviors we classified as ‘‘inactive’’. Inactive behaviors were
epochs of prolonged cessation of movement that were most
commonly preceded by nesting behaviors. Nesting behaviors were
recognized as repeated circular movement of the mouse near the
sides or corner of the cage and/or movement of bedding to form a
nest. During periods of inactivity, the mouse was often curled,
minimizing the body volume to surface ratio. Most inactivity bouts
occurred in corners, although some were observed along the sides of
the cage and even under the wheel. Since these behaviors
undoubtedly included sleep bouts, it was not surprising that they
had a roughly opposite temporal pattern to wheel running in both
WT and DKO mice (Fig. 1C). Moreover, the total time spent in
this behavior was not different between genotypes (WT:
2791.06376.8 s/mouse; DKO: 3287.86317.1 s/mouse; p.0.05;
Fig. 1D). Interestingly, DKOs had about twice as many bouts of
inactivity as WTs (WT: 3.860.5/mouse vs. DKO: 7.760.9/mouse;
p,0.05; Fig. 1E) and the average bout duration was about half
of that measured in WT mice (WT: 963.76180.5 s, DKO:
506.10643.0 s; p,0.05; Fig. 1F, left). As can be seen in the
cumulative inactivity bout duration (Fig. 1F, right), the range of
inactivity bout durations was similar for DKO and WT mice, but
there were many more bouts of shorter duration in the DKOs (K-S
test, p,0.05). Since these bouts were largely made up of time asleep,
these data indicate that DKO mice have an inability to maintain
consolidated rest behavior, presumably as a result of the sleep and
wake fragmentation which has previously been extensively
documented in orexin ligand knockout and orexin-ataxin-3
transgenic mice [26,27] and noted for DKO mice [13].
DKO mice exhibited spontaneous behavioral arrests
A striking feature of the DKO mice was the occurrence of
spontaneous behavioral arrests that appeared similar to those
described for mice lacking the prepro-orexin peptide [9] or orexin
neurons [26]. These arrests typically appeared as a collapse in
posture with the head and tail laying on the bedding and with the
body elongated or covering the limbs. These arrests were generally
quite obvious since they were preceded by purposeful motor
activity and were sudden in their onset and offset (see video S1).
During these arrests, the mice often showed brief phasic
movements of the head, tail or limbs. Indeed, a quivering or low
amplitude jerky rocking motion was often observed during the
attack (see video S2) and often occurred just before resumption of
purposeful behavior. Such behaviors were never observed in WT
mice. To score these events as full arrests, we required twenty
seconds of purposeful behavior prior to and following, at least a
temporary cessation of voluntary movement (.5 s). As defined,
these arrests likely included both the abrupt and the more gradual
onset arrests described by Willie et al. (2003) in OX2R2/2 mice
and orexin ligand KO mice.
In addition to full arrests, we sometimes observed episodes
where movements ceased only briefly (,5 seconds) and head
movements or attempted ambulation continued throughout the
attack (see video S3). These events were reminiscent of cataplectic
attacks that did not proceed to completion in narcoleptic canines
and in humans where only some muscle groups become affected
[28]. These incomplete attacks also sometimes preceded full
arrests and were often initially apparent as a change in gait, which
was then followed by a full loss of body support (see video S4). We
found that approximately 45% of these ‘‘partial’’ arrests went on
to full arrests but these partial arrests were not obligate precursors
of full arrests since only about 20% of full arrests were preceded
by such behaviors. These appeared similar to reported ‘‘gait
disturbances’’ described in the orexin knockouts [9] which would
either resolve or progress to a complete arrest. Indeed, a com-
parable number (27%) of arrests were preceded by these gait
disturbances in orexin knockouts.
As also noted in the original report of behavioral arrests in
orexin ligand knockout mice [9], we found that the number of
arrests varied greatly among DKO mice. By counting all arrests in
the three hour recording period for twenty DKO mice, we found
that four mice did not exhibit any arrests, while three exhibited
over twenty. Seven mice had between ten and twenty arrests while
five mice experienced fewer than ten (Fig. 2A). In addition, for any
given mouse, the duration of each arrest varied considerably. This
is indicated in Fig. 2A by the range of arrest durations which is
plotted along with the mean arrest duration for each mouse. The
mean arrest duration across mice was 42.266 s (n = 16) which is
comparable to the mean arrest duration in ataxin-3 mice and
ligand knockout mice which ranged from 41 s to 66 s [9,11,26,27].
We also found that the behavioral arrests were not uniformly
distributed across our recording session (Fig. 2B). Few arrests
occurred in the initial 30 minutes before the room lights went out
Narcolepsy in Orexin Receptor Null Mice
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and arrest frequency increased after light offset. In the first
30 minutes (before lights out), there was an average of only 0.7
arrests/mouse which occupied 21.3614.8 s/mouse (n = 20). This
increased to an average maximum of 3 arrests/mouse in the
30 minutes beginning two hours after recording onset (1.5 hours
after lights out) which occupied 99.3627.4 s/mouse (n = 20) of
this period. On average, the time spent in arrests was well
correlated with the time spent wheel running (Pearson’s r = 0.97
for mean time in arrest vs. mean time wheel running) and is
consistent with the idea that access to the running wheel promotes
behavioral arrests in narcoleptic rodents [25].
To determine how variable behavioral arrests were across
recording sessions, we recorded eight mice in three successive
recording sessions separated by several days (Fig. 2 C). While there
was great variability between mice within each recording session,
and there was considerable variability for each mouse between
sessions, the group average was not statistically different across
sessions (p = 0.72, repeated measures ANOVA). Thus, the group
average of total time in arrest was a stable measure of behavioral
arrests across recording sessions.
To address the behavioral context in which arrests occurred, we
examined the behaviors in the twenty seconds before and after
Figure 1. Wheel running and Inactivity in DKO and WT mice. (A) Average (6 SEM) time spent wheel running per mouse measured in 30-
minute bins across the entire recording session for DKO and WT mice. (B) The average (6 SEM) time per animal over the three-hour recording period
spent wheel running. (C) Average (6 SEM) time spent ‘‘inactive per mouse measured in 30-minute bins across the entire recording session. (D) The
average (6 SEM) time per mouse spent inactive for the three-hour recording session. Both the temporal pattern and amount of wheel running and
inactivity were similar in DKO and WT mice (E) In contrast, there were many more bouts of inactivity in DKO mice (mean6 SEM). In E and F * denotes
p,0.05 by a one-way ANOVA. (F, left) Moreover, inactivity bouts duration were shorter (mean 6 SEM) in DKO mice. (F, right) Cumulative distributions
of inactivity bout duration. Bouts were significantly shorter in DKO mice (K-S test p,0.05).
doi:10.1371/journal.pone.0018697.g001
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Figure 2. Behavioral arrests in DKOmice. (A) Behavioral arrests in individual DKO mice. Left scale shows the total number of behavioral arrests in
the three hour recording period by mouse (bars). Right scale shows the average duration of all recorded behavioral arrests (s; filled symbol) with the
shortest and longest bouts indicated by the whiskers. (B) Mean (6SEM) total time per animal spent in behavioral arrest per 30 min bin shows that
time spent in arrests increased substantially after the lights went out. (C) Total time per session for each mouse was variable (open symbols) but the
mean (6SEM) time per mouse was stable across sessions (filled symbols). (D) Distribution of DKO behaviors prior to (1) and after (2) behavioral arrests.
doi:10.1371/journal.pone.0018697.g002
Narcolepsy in Orexin Receptor Null Mice
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arrests for all DKO mice used in this study. Arrests in DKO mice
were most often preceded by ambulation (42.3%). This was
followed in frequency by wheel running (33.3%) and grooming
(20.4%) while only a small fraction of the arrests were preceded by
eating or burrowing (total of 4%). Arrests typically ended by an
abrupt resumption of activity. The most common of these
activities was ambulating (40.6%), followed by grooming
(21.6%), eating or drinking (17.1%; 13.5% respectively), wheel
running (6.3%) and burrowing (0.9%). Interestingly, these DKO
mice were much more likely to eat or drink just after an arrest than
just prior to one (Fig. 2D1, 2). These behaviors preceding arrests in
DKO mice occurred with similar frequency prior to arrests in
ligand knockouts and ataxin-3 mice [9,26]. For example, 41% of
the arrests in ligand knockout mice and 56% of arrests in the
ataxin-3 mice were preceded by periods of ambulation. Similarly,
23% of the attacks in ligand knockouts and 30.3% of attacks in the
ataxin-3 mice occurred after grooming. Collectively, these data
indicate that DKO mice display a narcolepsy-like phenotype that
is similar to that reported for mice lacking orexin peptides.
Behavioral arrest lifetimes are exponentially distributed
To gain insight into the processes governing expression of
behavioral arrests, we examined the distribution of arrest
durations. This is illustrated for full arrests in Figure 3A with the
distribution of just partial arrests superimposed. Partial arrests
made up only a small fraction of all arrests and they were on
average, shorter in duration than full arrests. The mean duration
for all arrests was 30.961.8 s (n = 267 from 16 mice) compared to
33.162.2 s for full arrests (n = 227) and 18.762.2 s (n = 40) for
partial arrests. It can also be seen that the arrest duration
distribution was approximately exponential in shape. To test this,
we conducted a survival analysis of full arrests (Fig. 3B) where the
fraction of full arrests (n = 227) lasting longer than each indicated
duration is plotted on log-log scales. Since recent studies have
found that the lifetimes of waking episodes are distributed as a
species-invariant power law and lifetimes of non-REM sleep are
distributed exponentially [29,30,31], we compared full behavioral
arrest lifetimes to both power and exponential distributions. If
arrest durations were distributed as a power function (i.e. arrest
lifetime,t2alpha) they would decay linearly on this graph as
indicated by the best fit power function (dashed line; alpha= 0.64).
Clearly, survival of arrest lifetimes decayed faster and were well fit
by an exponential distribution (arrest lifetime,e2t/tau) especially
for durations less than 60 seconds as indicated by the solid line.
The characteristic time of this best-fit exponential (tau= 26.7 s),
which is also the mean of an exponential distribution, agreed well
with the actual mean of all full arrests (33.162.1 s, n = 227). This
finding indicates that once DKO mice enter a full behavioral
arrest, the time spent in that arrest is well described by an
exponential distribution. At the long end of the distribution
(.60 sec), which comprised ,13% of the arrests, there was a
cluster of arrests with durations around at,100 seconds that were
longer than expected for an exponential distribution. These may
reflect rare arrests that are governed by different kinetics or arrests
that transition into a sleep state. For example, REM sleep lifetimes
are exponentially distributed for short durations but have another
mode around 100 s [32,33].
Low doses of physostigmine acutely exacerbate
narcolepsy in DKO mice within the first hour of recording
To investigate the potential role of cholinergic systems in
regulating behavioral arrests, we first studied the effect of altering
cholinergic transmission systemically with IP injections of
physostigmine or atropine. We then studied the effects of altering
cholinergic transmission locally in the pontine reticular formation
by microinjecting neostigmine or neostigmine and atropine. In
each of these experiments we focused on full behavioral arrests,
which we considered to be manifestation of narcolepsy.
The cholinesterase inhibitor physostigmine was delivered IP at
three doses (0.01, 0.03, 0.08 mg/kg) to twenty mice (DKO, n= 10;
WT, n=10) one half hour prior to video recording (one hour prior
to dark phase). We found that the lower two doses of
physostigmine produced an increase in the time spent in full
arrest within the first hour of recording (Fig. 4A,B). During this
period, the mean time spent in arrest per mouse differed
Figure 3. Behavioral arrest duration in DKO mice are well fit by
an exponential distribution. (A) Distributions of full (black bars) and
partial (grey bars) arrest bout durations. (B) Survival analysis of full arrest
bouts. Fraction of bouts longer than each duration are plotted on a
double log scale (open symbols). The best fit exponential (solid line)
and power functions (dashed line) are superimposed. Arrest lifetimes
are poorly fit by a power function but very well fit by the exponential. A
small fraction (,13%) of arrests are longer than expected for the best fit
exponential relation and clustered around 100 s.
doi:10.1371/journal.pone.0018697.g003
Narcolepsy in Orexin Receptor Null Mice
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significantly across doses (p,0.05, 2-way ANOVA). It increased
from 36.5613.5 s following saline injections to 160.9663.9 s
(0.01 mg/kg; p,0.05) and to 118.9642.6 s (0.03 mg/kg, p,0.05)
following physostigmine injections (Fig. 4B). Consistent with the
time course of physostigmine actions [34,35], which was expected
to elevate brain ACh levels for ,1 hour [36], there was no
difference in the time spent in arrest at later recording times.
Strikingly, at the highest dose (0.08 mg/kg) the early increase in
the time spent in arrest was absent (28.5614.8 s, not different
from Saline, p.0.05; Fig. 4A).
The increase in the time spent in arrest produced by low doses of
physostigmine could be due to an increase in the number and/or
duration of the arrests. The number of arrests differed significantly
by dose (p,0.05, 2-way ANOVA) and were significantly increased
compared to saline at the two lower doses (p,0.05; Saline: 1.160.4,
Physo 0.01 mg/kg: 2.961.1; Physo 0.03 mg/kg: 2.661.1) but not
at the highest dose (Physo 0.08 mg/kg: 0.960.5, p.0.05; Fig. 4C).
The mean arrest bout duration also differed by dose (p,0.05, 2-way
ANOVA; Saline: 25.2 s64.7; Physo 0.01 mg/kg: 40.2 s65.5;
Physo 0.03 mg/kg: 51.2 s611.9; Physo 0.08 mg/kg: 18.5 s62.5)
Figure 4. The number of behavioral arrests in DKO mice increased following low doses of systemic physostigmine. (A) Mean (6 SEM)
time per mouse spent in full behavioral arrests are plotted in 30 min bins across the entire recording period following IP injections of saline and three
concentrations of physostigmine (0.01, 0.03 and 0.08 mg/kg). Following the two lower doses, time in arrest was elevated in the first recording hour
(boxed area). The grey background indicates dark period of the recording. (B) Mean (6 SEM) time in full behavioral arrest in the first recording hour
following each dose. Time spent in arrest differed significantly across doses (p,0.05, 2-way ANOVA) and was elevated ,3-fold following the two
lowest physostigmine doses but was not elevated following the highest dose. (C) Mean (6 SEM) number of full behavioral arrests per animal in the
first recording hour varied by dose (p,0.05, 2-way ANOVA). The two lower doses increased the number of full behavioral arrests compared to saline.
* denotes p,0.05 by post-hoc testing for B and C. (D) Cumulative distributions of arrest bout duration over the first recording hour. Distributions
following saline vs. 0.01 mg/kg physostigmine (left; open symbols) and saline vs. 0.03 mg/kg physostigmine (right; open symbols) were compared
using the Kolmogorov-Smirnoff test. Arrest bout durations following physostigmine were not different than those following saline although some
longer bouts were present. The cumulative distribution of all bouts following saline is also shown (dark line) and it superimposes over the distribution
following physostigmine. (E) Mean time spent in the inactive state in the first hour of recording following saline and each dose of physostigmine. (F)
Mean time spent wheel running in the first hour of recording following saline and each dose of physostigmine.
doi:10.1371/journal.pone.0018697.g004
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although post-hoc comparisons were significant only between the
0.03 mg/kg dose and the saline and 0.08 mg/kg doses. Interest-
ingly, the distributions of bout durations were not significantly
different (K-S test; p.0.05; Fig. 4D) even though there were some
longer bouts present following low-doses of physostigmine. In fact,
the distribution of bout durations in the first hour following low
doses of physostigmine completely overlapped with the distribution
of arrest durations from the whole recording period following saline
injections, which also included some long bouts (thick line in
Fig. 4D). This indicates that following physostigmine injection, the
appearance of a few longer arrest bouts, which are rarer than short
bouts, would be expected simply because there were more arrests.
Collectively, these data suggest that low doses of physostigmine
increase the likelihood of full arrests without altering arrest
dynamics.
To determine if these doses of physostigmine altered behavioral
arrests due to general changes in arousal, we also examined the
effects of physostimine on wheel running and inactivity (Fig. 4E,F).
We found that the time spent in these activities was not significantly
different across drug treatment conditions by 2 way ANOVA with
condition and mouse as factors (p= 0.31, wheel running; p= 0.20,
inactivity). This indicates that these concentrations of physostigmine
alter expression of arrests without producing detectable changes in
these measures of arousal or motor activity.
Importantly, none of these physostigmine doses produced
behavioral arrests in WT mice. In some cases, it produced side
effects such as body tremors or spasms, however these events were
rare, brief and observed in both WT and DKOmice. None of these
events resembled the behavioral arrests observed in the DKOmice.
Thus, we conclude that physostigmine and the resulting enhance-
ment of cholinergic transmission promotes narcoleptic attacks in
DKO mice and that the absence of orexin signaling is necessary for
this effect.
Atropine significantly attenuates behavioral arrests in
DKO mice
To further test the involvement of cholinergic mechanisms, we
administered the muscarinic receptor antagonist, atropine to
seventeen mice (DKO, n= 10, WT, n= 7) by IP injection
(0.5 mg/kg body weight) thirty minutes prior to video recording.
Atropine was expected to reach its highest plasma concentration
within two hours after injection [37] and has a four hour half-life
[35]. We found that this dose decreased the number of full arrests
compared to saline injection. Eight out of the ten DKO mice
tested exhibited fewer or no behavioral arrests following injection
of atropine compared to saline and the average time in arrest
appeared lower during the recording session (Fig. 5A). Across the
entire recording session, DKO mice receiving atropine injections
Figure 5. The number of behavioral arrests in DKOmice decreased following systemic atropine. (A) Mean (6 SEM) time per mouse spent
in full behavioral arrests are plotted in 30 min bins across the entire recording period following IP injections of saline (open symbols) and atropine
(0.5 mg/kg; filled symbols). Grey area indicates dark phase. (B) Mean (6 SEM) time per mouse spent in arrest over the entire recording following
saline and atropine. The time spent in arrest was significantly reduced following atropine. (C) Mean (6 SEM) number of arrests per mouse over the
entire recording period following saline and atropine. Number of behavioral arrests were also significantly decreased. In B and C * denotes p,0.05
with two-way ANOVAs. (D) Cumulative distributions of arrest durations. Distributions following saline (open symbols) vs. atropine (closed symbols)
were compared using the Kolmogorov-Smirnoff test and were not different. (E) Mean (6 SEM) time spent in the inactive state was not different
following saline and atropine. (F) Mean (6 SEM) time spent wheel running was also not different following saline and atropine.
doi:10.1371/journal.pone.0018697.g005
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spent significantly less time in full arrests (Saline: 475.9667.9 s,
Atropine: 325.1692.7 s, p,0.05, 2-way ANOVA; Fig. 5B). This
decrease was attributable to significantly fewer behavioral arrests
(Saline: 12.562.2, Atropine: 6.862.2, p,0.05, 2-way ANOVA;
Fig. 5C) rather than a change in the mean duration of these arrests
(Saline: 44.467.1 s, Atropine: 54.5610.5, p.0.05, 2-way AN-
OVA). In fact, the full arrest bout duration distribution following
saline and atropine completely overlapped (KS-test p.0.05;
Fig. 5D). Thus, atropine, like IP physostigmine, altered the time
spent in full arrests but did not change the duration of arrests once
they occurred.
To determine if this effect of atropine was specific for behavioral
arrests, we examined the wheel running and inactivity behavior
following injections of atropine and saline. We found that neither
the number, time, nor bout duration of these activities were altered
following atropine (p.0.05, 2 way ANOVA for each), even
though the number of behavioral arrests was reduced (Fig. 5E, F).
Thus, the effect of this dose of atropine on behavioral arrests did
not appear to result from overt changes in overall mouse activity.
Collectively, these data support the idea that muscarinic
transmission promotes the expression of behavioral arrests in
mice deficient in orexin signaling, but not in WT mice. Moreover,
since the number of arrests was altered without affecting arrest
durations, these data suggest that cholinergic mechanisms are not
involved with establishing the dynamics of the arrests but play a
role in regulating their expression. These findings agree well with
atropine effects on spontaneous behavioral arrests in orexin ligand
KO mice studied under a food shift paradigm (Willie, 2005). In
that paradigm, ligand KO mice had a higher rate of arrests than
observed for DKO mice studied here in their home cages.
Nevertheless, atropine (0.5 mg/kg; IP) decreased the rate of
attacks in ligand KO mice to ,15% of the rate observed following
vehicle injection.
Pontine microinjections of neostigmine increased the
frequency of full behavioral arrests
In light of the evidence linking cholinergic transmission in the
pontine reticular formation to the generation of REM sleep signs
and canine cataplexy, we sought to determine whether promoting
cholinergic transmission in this region influences mouse narcolep-
sy. We targeted the PnO or PnC in WT (n= 9) and DKO (n= 11)
mice for microinjection (50 nl) of either ACSF, neostigmine
(62.5 mM, 0.95 ng) or a mixture of neostigmine (62.5 mM, 0.95 ng)
& atropine (111 mM, 3.8 ng) and then scored their behavior.
Injections sites for three mice (2 DKO; 1 WT) were outside these
nuclei so we excluded their data from further analysis. Figure 6
illustrates the injection site locations for the eight WT and nine
DKO mice used for analysis. Injection sites were found over a
,1 mm rostral to caudal extent between 24.36 mm and
25.34 mm caudal to bregma and were plotted onto two sections
demarking the midsections of the rostral and caudal halves of this
range. Injection sites in the DKO mice (filled circles) were located
in both the PnO and PnC while injection sites in the WT mice
(open circles) were located in the PnO.
Since we were concerned that the stress of the implants or
microinjection might influence the pattern of arrests, we first
compared recordings made prior to implantation with recordings
made following ACSF microinjections. This revealed that the
same DKO mice had fewer arrests after implantation and
microinjection. The mean number of arrests/mouse measured in
three hours was reduced from 12.562.3 prior to implantation to
0.660.3 after implantation and microinjections of ACSF
(p,0.05). The time spent in arrest was reduced from an average
of 534.0690.7 s to 37.5618.9 s (p,0.05). There was, however, no
significant difference in the distribution of arrest bout durations
(K-S test p.0.05), suggesting that the implantation/injection
mainly reduce the expression of behavioral arrests but did not
influence their dynamics once initiated.
We next examined the effects of neostigmine microinjections.
We found that 7 out of the 9 DKO mice exhibited more arrests
after neostigmine with the average number of arrests increasing
more than 4-fold (ACSF: 0.660.3, Neo: 4.161.0, p,,0.05, 2-
way ANOVA) over the three hour recoding period. This resulted
in a large increase in the total time spent in full behavioral arrests
(ACSF: 37.5618.9 s, Neo: 241.7635.8 s, p,0.05, 2-way AN-
OVA; Fig. 7A,B). However, neither the mean bout duration was
altered (p.0.05 2-way ANOVA), nor was the distribution of arrest
durations (Fig. 7C) altered, even though the number of arrests was
increased (K-S test P.0.05).
To determine if the neostigmine effect on behavioral arrests
depends on muscarinic receptor activation, we microinjected a
solution of neostigmine with atropine, in order to concurrently
block muscarinic receptors. Under these conditions, the number of
arrests was not different from the number following microinjec-
tions of ACSF alone (Neo+Atr: 0.960.4, p.0.05). Moreover, the
total time spent in arrest (Neo+Atr: 48.1625.6 s) was also not
different (Fig. 7A,B) but was significantly less than that following
Neo alone (p,0.05; Fig. 7B). Despite this, the distribution of arrest
durations was not significantly different from that following ACSF
or Neo alone (Fig. 7C; K-S test p.0.05).
Figure 6. Locations of neostigmine and saline microinjection
sites in the pontine reticular formation. Injection sites ranged
from 24.36 mm to 25.20 mm from Bregma and were recovered in the
PnO or PnC. Open symbols are the sites from WT mice and closed
symbols are the sites from DKOs. See text for further explanation.
doi:10.1371/journal.pone.0018697.g006
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In contrast to the effect in DKO mice, pontine microinjections
of neostigmine into WT mice never produced behavioral arrests or
behaviors resembling arrests, indicating that the ability of this dose
of neostigmine to promote behavioral arrests required the absence
of orexin signaling.
Given the preponderance of rostral injection sites in the WT
mice, we compared the effectiveness of neostigmine at rostral and
caudal microinjection sites in DKO mice to see if injection
location could account for the absence of arrests in WT mice
following microinjections. We found that the total time spent in
arrest was highly dependent on the injection condition but was not
dependent on injection location (PnO or PnC; 2 way ANOVA,
drug: p,,0.05; location: p= 0.69). Neostigmine microinjections
into the PnC increased the mean time in arrest from 29.5624.9 s
(ACSF) to 229.5648.0 s (Neo; p,0.05, n= 4) while microinjection
of Neo+Atr did not significantly increase the mean time spent in
arrest (90.0652.3 s; p = 0.35, n = 4). Similarly, neostigmine
microinjections into the PnO increased the mean time in arrest
from 43.8629.8 s (ACSF) to 251.4655.2 s (Neo; p,0.05, n= 5)
while microinjection of Neo+Atr did not significantly increase the
mean time spent in arrest (14.669.1 s; p = 0.58, n= 5). Thus, in
DKO mice, neostigmine injections into the PnO region were as
effective as those into the PnC region indicating that the lack of
arrests following neostigmine injections in the WT mice was not
due the more rostral microinjection sites. Collectively, these data
indicate that promoting endogenous ACh release in the pontine
reticular formation of DKO, but not wild type mice increases the
number, but not the duration, of narcoleptic attacks.
Finally, to determine if the neostigmine effect on DKO mice
was specific to behavioral arrests, we examined the impact of these
microinjections on wheel running and time spent in the inactive
state. The average time the DKO mice spent in the inactive state
and interacting with the running wheel is illustrated in Figure 7D
and E, respectively. Neither the total time spent inactive, nor the
time on the running wheel were significantly different across drug
conditions based on ANOVAs (Inactivity: p = 0.08; Wheel
Running: p = 0.21) although there were trends toward greater
time on the wheel and less time inactive following the neostigmine
microinjections. These data indicate that at the dose of
neostigmine utilized, enhanced muscarinic transmission in the
pontine reticular formation is sufficient to increase expression of
behavioral arrests without producing a significant impact on
overall levels of activity in DKO mice. These findings confirm that
these regions, which are implicated in cholinergic control of REM-
Figure 7. Neostigmine microinjection sites into the PnO/PnC increased behavioral arrests in DKO but not WT mice. (A). Mean (6 SEM)
time per mouse spent in full behavioral arrests are plotted in 30 min bins across the entire recording period following PnO/PnC microinjections of
ACSF (open squares), neostigmine (closed triangles) and neostigmine+atropine (open triangles). Grey area indicates dark phase. (B) Mean (6 SEM)
time per mouse spent in arrest over the entire recording following ACSF, neostigmine and neostigmine+atropine. Neostigmine increased the time
spend in arrest compared to ACSF and neostigmine+atropine, * denotes p,0.05 based on post-hoc testing following a significant two-way ANOVA
(p,0.0002). The difference between ACSF and neostigmine+atropine was not significant (p.0.05). (C) Cumulative distributions of arrest bout
duration over the entire of recording. Distributions following ACSF, neostigmine or neostigmine+atropine were not different as compared using the
Kolmogorov-Smirnoff statistics. (D) Mean (6 SEM) time spent in the inactive state. (E) Mean (6 SEM) time spent wheel running. Values in D and E
were not statistically different across microinjection conditions (p.0.05, 2-way ANOVAs).
doi:10.1371/journal.pone.0018697.g007
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sleep signs in species including mouse [23], contain site(s) at which
cholinergic transmission regulates the expression of rodent
narcolepsy.
Discussion
The major findings of this study are: 1) DKO mice exhibit
fragmented rest states and behavioral arrests which are similar to
narcolepsy symptoms observed in orexin deficient mice; 2) Low
systemic doses of physostigmine and microinjections of neostig-
mine into the pontine reticular formation increased the number of
behavioral arrests in DKO mice while having no effect upon WT
mice; 3) A systemic dose of atropine decreased the number of
arrests, and pontine microinjections of atropine prevented the
increase in arrests induced by pontine microinjections of
neostigmine; 4) The lifetimes of spontaneous behavioral arrests
were exponentially distributed. Although altered cholinergic
transmission changed the number of arrests, it did not change
the distribution of arrest durations. As discussed below, these
findings have a number of implications for both understanding the
neural adaptations resulting from orexin signaling loss and for the
function of the cholinergic system in regulating narcoleptic attacks.
Are DKO mice a phenocopy of orexin ligand deficient
mice?
The present observations suggest that DKO mice are a
phenocopy of the orexin peptide deficient mice, at least with
regard to the narcolepsy phenotype. For example, DKO mice
showed evidence of an inability to maintain consolidated rest
behavior compared to wild type mice (Fig. 1E, F), which is
consistent with the instability in behavioral states described for
ligand KO mice [27]. DKO mice also displayed unambiguous
behavioral arrests that were never observed in WT mice. These
arrests were similar in number, duration, variability and
behavioral context to the behavioral arrests reported for orexin
deficient mice. Moreover, the average number of arrests, and the
time spent in arrests, increased with the time spent on the running
wheel. This relation is consistent with the observation in orexin
knockout mice that access to a running wheel promotes cataplexy
[25]. Given that mild sleep deprivation doesn’t increase cataplexy
in ligand knock out mice [27], it is likely this relation relates to the
enhanced motor activity or associated emotional content rather
than any sleep debt accumulated during the time running. In
addition to full arrests, DKO mice displayed gait disturbances
and/or partial attacks which were similar in character and
frequency to those reported for orexin knockout mice and
appeared similar to partial cataplexy observed in human
narcoleptics. In contrast, these motor alterations were never
observed in OXR2 KO mice [11] underscoring a role for OX1Rs
in suppressing these attributes.
Willie et al. [11] delineated two types of behavioral arrests in
OX2R KO and ligand KO mice. ‘‘Abrupt’’ arrests interrupt
ongoing active behavior and appear analogous to cataplexy, while
‘‘gradual’’ arrests begin from quiet waking and are more like sleep
attacks. Both types of arrests were observed in ligand KO mice
while abrupt arrests were rare in OX2R mice suggesting that
residual signaling through OX1Rs may suppress them. While we
could not systematically delineate gradual arrests using our top-
mounted cameras, we observed unambiguous abrupt arrests (see
supplemental videos) in DKO mice supporting a role for OX1Rs
in suppressing these events. Using a side mounted camera we have
also observed gradual arrests in DKO mice which began with
head nodding from a stationary position (Ikinko and Leonard,
unpublished observations). Willie et al. [11] found that gradual
arrests in ligand KO mice, unlike those in OX2RKO mice were
often longer and transitioned into a REM-like state that included
rocking movements. DKO mice also showed rocking movements
during behavioral arrests including those with gradual onset,
further supporting a role for OX1Rs in suppressing motor aspects
of these attacks.
The fraction of arrests we observed corresponding to cataplexy
per se, could not be determined since our mice were not
instrumented. The current consensus definition requires simulta-
neous recording of behavior, EEG and EMG [38] and requires at
least ten seconds of immobility, an EEG dominated by theta
activity, nuchal atonia and at least forty seconds of waking
preceding the episode. While we only required greater than five
second of immobility to define our arrests, the vast majority of
arrests we observed were ten seconds or longer (see Fig. 3A) in
accordance with the consensus definition. We also required only
twenty seconds of purposeful behavior preceding an arrest. The
consensus requirement of forty second effectively disambiguates
episodes of cataplexy from direct transitions into REM sleep from
waking (DREMs) which occur even in normal mice [39]. In
normal mice, DREMs are often re-entries into REM sleep
following a brief awakening and occur mainly in the light phase
(Fujiki et al. reported only 1 of the 24 DREMs seen in normal mice
occurring during the dark phase). Since our recordings were
mainly conducted in the dark phase and since we never observed
arrests in wild-type mice, it is unlikely that any of our scored
arrests were normal DREMs erroneously scored as behavioral
arrests. Moreover, requiring forty seconds of prior waking
underestimates the number of cataplectic events in narcoleptic
mice in the dark phase (sensitivity ,75%) while shortening this to
twenty seconds improves their detection (sensitivity ,86%, [39]).
Thus, our behavioral arrests are likely to accurately reflect both
cataplexy and sleep attacks in DKO mice. Going forward, it will
be important to measure EEG and EMG in conjunction with
video to delineate cataplexy from sleep attacks, especially since
only about 80% of abrupt arrests in ligand KO mice initiate with
REM-like EEGs [11].
Collectively, our results suggest that the constitutive loss of the
two known orexin receptors is sufficient to recapitulate the
narcolepsy phenotype of the ligand KO and underscore the
importance of OX1Rs in suppressing cataplexy and other motor
signs of the phenotype.
Altered muscarinic transmission influenced the
expression of narcoleptic attacks in DKO mice
Findings with low systemic doses of physostigmine and atropine
indicated that, like narcoleptic canines, muscarinic transmission
regulates the expression of narcoleptic attacks in DKO mice.
While the lowest two doses of physostigmine (0.01; 0.03 mg/kg)
produced ,3-fold increase in the time spent in arrests within the
first hour of recording, the highest dose (0.08 mg/kg) failed to
produce such an increase, and the time in arrest remained low
throughout the recordings. Both peripheral and central actions of
physostigmine may have contributed to this unusual dose
dependence. For example, autonomic side effects such as
bradycardia or tremors might have contributed to suppressing
arrests at the highest dose, although signs of tremor were very rare.
Centrally, perhaps cholinergic REM promoting actions predom-
inated at low doses, while at higher doses, wake-promoting actions
predominated and suppressed REM-promoting activity. This
would be consistent with Datta’s data indicating that moderate
stimulation of PPT cholinergic regions elicits REM signs while
strong stimulation elicits waking [40] with the attendant
suppression of REM-sleep signs. Nevertheless, since neither wheel
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running nor inactivity behaviors were statistically different across
physostigmine concentrations, any wake promotion by physostig-
mine was too subtle for our measures.
Since alterations of cholinergic transmission by the same doses of
systemic physostigmine or pontine neostigmine did not produce
arrests in WTmice, our data also indicate that adaptations from the
loss of orexin receptor signaling leads to better coupling between
cholinergic systems and the circuits that suppress muscle tone and
locomotion. As noted in the Methods, the pontine neostigmine dose
that increased arrests in DKO mice was more than ten times lower
than a dose used to induce a REM-like state in WT mice [23] and
did not produce obvious alterations in behavior in our WT control
mice. This is consistent with observations in canines, where much
higher doses of the cholinergic agonist carbachol delivered to the
pontine tegmentum or basal forebrain are required to produce
atonia in WT dogs than are required to trigger cataplexy in
narcoleptic dogs [41,42]. The specific neural changes that enhance
this coupling in the absence of orexin receptor signaling are not yet
clear and several mechanisms alone or in combination may
contribute. For example, muscarinic transmission may be more
effective at inhibiting REM-off inhibitory neurons in atonia circuits
due to the absence of an opposing orexin action [43,44]. In
addition, post-synaptic sensitivity to ACh may be increased on these
neurons, as suggested by receptor binding studies in the pontine
reticular formation of the narcoleptic canine, which found elevated
mAChRs [45]. Another possibility is that mesopontine cholinergic
transmission may be enhanced in DKO mice, as appears to be the
case in narcoleptic canines [46]. Consistent with this, we found
higher message levels for enzymes necessary for ACh synaptic
transmission in LDT samples from DKOmice [47]. These changes
suggest mesopontine cholinergic transmission is enhanced in DKO
mice and that inhibition of cholinesterase might have more
profound consequences in DKO mice than WT mice.
Dynamics of behavioral arrests and its modulation by
cholinergic transmission
Perhaps the most striking findings of this study are: 1) that
lifetimes of behavioral arrests are well described by an exponential
distribution and 2) that neither systemic (see Figs. 4D, 5D) nor
local (Fig. 7C) modulation of cholinergic transmission detectably
changed this distribution. These observations have significant
implications for the mechanisms governing the expression of
narcoleptic attacks.
First, the exponential distribution suggests that the termination
of spontaneous full behavioral arrests is governed by a process that
is random and memory-less, like a continuous Markov process. It
implies that the probability of exiting an arrest is constant per unit
time and is not influenced by the number or duration of prior
arrests. From this perspective, it makes sense that when the
number of arrests in the first hour of recording was increased by
systemic physostigmine, a few arrest bouts of longer duration
would be observed (see Fig. 4). This finding is also consistent with
the exponential lifetime distribution of cataplexy noted in orexin
ligand knockouts [30].
A second implication relates to the role of cholinergic neurons in
the expression of behavioral arrests. While the frequency of arrests
was increased by both systemic physostigmine and pontine
microinjections of neostigmine and was decreased by systemic
atropine, the distribution of arrest durations was not altered. Thus,
to the degree that cholinergic transmission was altered by our
treatments, muscarinic transmission influenced transitions into
behavioral arrests but played no role in stabilizing or terminating
these arrests. That is, the kinetics governing transitions out of the
arrest state were not influenced by muscarinic transmission since
they proceeded similarly whether or not muscarinic transmission
was altered. This implication places important constraints on the
possible neuronal circuits regulating these arrests.
Cholinergic enhancement of narcoleptic attacks and
REM-sleep circuits
A core element of the reciprocal-interaction model is that relief
from REM-off monoaminergic inhibition enables LDT/PPT
cholinergic REM-on neurons to drive REM sleep signs via
outputs to the pontine reticular formation (PnO, PnC and
sublaterodorsal tegmental region (SLD)) and thalamus (for review
see [16]). Extensive neurochemical studies of narcoleptic canines
are consistent with an imbalance in this circuit promoting
cataplexy. Like in narcoleptic canines, our findings in DKO mice
support a role for cholinergic systems in promoting cataplexy.
However, it is hard to reconcile this model with our finding that
arrest lifetimes were uninfluenced by altered cholinergic transmis-
sion. In this model, REM-on cholinergic activity also excites
REM-off monoaminergic neurons, critically linking cholinergic
outflow to the termination of REM sleep signs. Doses of
physostigmine that altered arrest frequency should also have
altered arrest duration if this circuit controls behavioral arrests.
Thus, our findings are inconsistent with this and other models
where cholinergic outflow sets the duration of behavioral arrests.
Of course, our findings do not mean that such a model might not
govern normal REM sleep, our findings are just inconsistent with
these circuits regulating the dynamics of behavioral arrests in
narcoleptic mice. However, evidence from pontine microinjections
of carbachol in normal rodents indicate that the main effect is to
increase the frequency rather than the duration of REM-like
events [48,49], suggesting a similar role for cholinergic systems in
generating REM signs in WT rodents.
Evidence from rodent studies has challenged the cholinergic-
monoaminergic hypothesis and emphasized the role of GABAergic
transmission in the SLD region [18], the ventrolateral periaqua-
ductal grey and lateral pontine tegmentum (LPT) for REM
switching [19,20,50]. Models derived from this work propose that
reciprocating REM-on and REM-off GABAergic interconnections
make up a core switch that determines the timing and duration of
REM atonia [21,22,50]. Our findings are more consistent with this
type of a model governing arrests and would be consistent with
cholinergic actions at several cell groups in these models. For
example, the arrangement proposed by Fuller et al. [21] in which
LDT/PPT REM-on cholinergic neurons inhibit the REM-off
LPT neurons but are not inhibited by the LPT would be consistent
with our findings since cholinergic REM-on neurons would be
outside the core switch and wouldn’t determine arrest duration,
yet enhanced cholinergic transmission would still promote arrests.
A limitation of these models, however, is that no mechanism to
terminate REM or arrest bouts are specified. One possibility
consistent with the constraint implied by our findings, would be a
use-dependent decay in REM-on GABAergic inhibition of REM-
off GABAergic neurons. This decay would set the arrest lifetime
and allow the termination of arrests to proceed independently of
cholinergic influences on the LPT REM-on inhibitory neurons.
Future approaches designed to selectively activate or inhibit these
neurons will be necessary to provide a strong test of these ideas.
Supporting Information
Video S1 IR video recording of a DKOmouse illustrates
the rapid onset and offset of a behavioral arrest. After
ambulation ceased, the mouse made several head movements
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before movement completely ceased. During the attack the mouse
also made some brief rocking movements.
(MOV)
Video S2 IR video recording of a DKO mouse whose
behavioral arrest is punctuated by multiple epochs of
quivering and rocking.
(MOV)
Video S3 IR video recording of a DKOmouse illustrates
incomplete behavioral arrests that resolves without
entering into a full arrest. It appears that movement is
impaired until grooming begins.
(MOV)
Video S4 IR video recording of a DKOmouse illustrates
a partial behavioral arrest that proceeded into a full
arrest with considerable rocking. Following the arrest, the
mouse quickly moved to drink from the water bottle.
(MOV)
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